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I. EXECUTIVE SUMMARY 
 
 Proposition 14 authorizes the state to sell $5.5 billion in general obligation bonds to 
support stem cell and other medical research, updating and renewing the program 
approved by voters in 2004. The research is aimed at developing treatments and cures for 
serious diseases and conditions like diabetes, cancer, HIV/AIDs, heart disease, paralysis, 
blindness, kidney disease, respiratory illnesses, and many more. Of the $5.5 billion, $1.5 
billion will be dedicated to the support of research and the development of treatments for 
diseases and conditions of the brain and central nervous system, such as Alzheimer’s 
disease, Parkinson’s disease, stroke, dementia, epilepsy, depression, brain cancer, 
schizophrenia, autism, and other diseases and conditions of the brain. If the proposition 
passes, the estimated cost to taxpayers over time will be $7.8 billion.1 
 
II. THE LAW 
  
A. Existing Law 
 
In 2004, California voters approved Proposition 71, which added a provision to the 
State Constitution affirming the right of researchers in California to conduct stem cell 
research.2 Proposition 71 also created the California Institute for Regenerative Medicine 
(CIRM) to provide grants to universities and other entities in California to support stem cell 
research, development of new treatments, clinical trials, new research facilities, and other 
related activities.3 The measure also established a governing board to adopt CIRM policies 
and allocate funds, three advisory working groups to help guide the governing board, and 
an independent oversight committee to review CIRM’s finances.4   
 
These grants were funded by $3 billion through the sale of public bonds; and the 
interest, another $3 billion, was payable from the state’s General Fund.5 As of June 2020, 
around $30 million remains available for grants.6 In the event that Proposition 14 does not 
pass, CIRM has been decreasing staff and plans to maintain only those needed to manage 






1  Proposition 14, LEGISLATIVE ANALYST’S OFFICE, 




5 California Proposition 71, Stem Cell Research Bond Initiative (2004), BALLOTPEDIA,  
https://ballotpedia.org/California_Proposition_71,_Stem_Cell_Research_Initiative_(2004) (last visited Oct. 7, 
2020). 





B. Relevant Peripheral Legislation 
 
1. California State Law 
 
California state law permits research on human embryonic stem cells, human 
embryonic germ cells, and human adult stem cells including somatic cell nuclear 
transplantation, that has been reviewed by a stem cell research oversight committee.8 This 
research is subject to the laws relating to the donation of tissue and the storage of 
embryos.9 California state law prohibits human reproductive cloning, however human 
reproductive cloning is not the same as embryonic stem cell research.10 Human 
reproductive cloning requires placing the embryos back into a uterine environment while 
embryonic stem cells are studied in a laboratory environment.11  
 
2. Federal Law 
 
On March 9, 2009, President Obama issued an executive order, “Removing Barriers 
to Responsible Scientific Research Involving Human Stem Cells.”12 This executive order 
removed limitations placed on research involving human embryonic stem cells created by 
President G.W. Bush in August 2001.13 
  
On June 5, 2019, the Trump administration announced that it will no longer allow 
government scientists working for the National Institutes of Health (NIH) to conduct studies 
that use fetal tissue, and university scientists seeking NIH funding for such studies must now 
have each proposal examined by an ethics advisory board.14 The board would be made up 
of 14 to 20 people from various backgrounds, including at least one theologian, one 
ethicist, one physician, and one attorney.15 No more than half of the panel members can be 
scientists.16 Even though this is not directly related to stem cell research, it provides a 





8 CAL. HEALTH & SAFETY CODE § 125300.  
9 CAL. HEALTH & SAFETY CODE §§ 125300–125320 
10 CAL. HEALTH & SAFETY CODE §§ 24185–24187; CAL. BUS. & PROF. CODE §§ 16004, 16105.  
11 What is cloning, and what does it have to do with stem cell research, EUROSTEMCELL, 
https://www.eurostemcell.org/what-cloning-and-what-does-it-have-do-stem-cell-research (last visited Sept. 22, 
2020)..  
12 Exec. Order No. 13505, 74 Fed. Reg. 10667 (Mar. 9, 2009). 
13 Id. 
14 Meredith Wadman, Trump Administration Restricts Fetal Tissue Research, SCIENCE (June 5, 2019, 2:26PM), 





3. Other States 
 
Nearly a dozen states have launched initiatives for funding stem cell research, 
though they have not contributed as much money as California.17 Like California, some 
states allocated funding to support stem cell research in response to the restrictions on 
federal funding by the Bush administration, including Maryland and New York.18 In 2006, 
Maryland passed the Maryland Stem Cell Act of 2006 and to date has awarded $165 
million to promote state funded stem cell research through the Maryland Stem Cell 
Research Fund.19 Similarly, in 2007, New York launched the New York State Stem Cell 
Science program (NYSTEM) to support stem cell research across the state of New York.20 To 
date, NYSTEM has awarded $396 million to New York institutions.21 
 




 A variety of sources fund stem cell research in California. These sources include: the 
federal government’s National Institutes of Health, private investors, and CIRM, each having 
different goals and abilities.22  
 
 Private sector investment generally occurs during the testing and development 
phase, rather than the initial basic research.23 Scientists have referred to the stage right 
before industry becomes interested in the research as the “Valley of Death.”24 It is an area 
where promising therapies often languish, because there is not enough federal funding to 
push the projects through to the later stages.25 CIRM has focused on funding the early 
research that leads to therapy ideas and fund projects that are in the Valley of Death 
stage, helping to keep good projects on track toward clinical therapies.26  
 
 
17 David Gorn, Will Voters Continue to Pour Money Into Stem Cell Research, HEALTH SHOTS NPR (Jan. 25, 2018), 
https://www.npr.org/sections/health-shots/2018/01/25/579727683/will-state-voters-continue-to-pour-money-into-
stem-cell-research (last visited Oct. 7, 2020). 
18 Hillary B. Alberta et al., Assessing State Stem Cell Programs in the United States: How Has State Funding 
Affected Publication Trends?, 16 Cell Stem Cell 115-118, (2016). 
https://www.sciencedirect.com/science/article/pii/S1934590915000089 (last visited Oct. 7, 2020). 
19 About Us, MSCRF MARYLAND STEM CELL RESEARCH FUND, https://www.mscrf.org/about-us (last visited Oct. 7, 
2020). 
20 About Us, NYSTEM NEW YORK STATE STEM CELL SCIENCE , https://stemcell.ny.gov/about-us-
0#:~:text=History,research%20across%20New%20York%20State (last visited Oct.7, 2020).  
21 Id. 
22 FAQ, CIRM CALIFORNIA’S STEM CELL AGENCY, https://www.cirm.ca.gov/about-cirm/cirm-faq#funding (last visited 
Sept. 22, 2020).  
23 How Stem Cell Research Is Funded, AMERICANS FOR CURES, https://americansforcures.org/stem-cells/how-stem-
cell-research-is-funded/ (last visited Sept. 17, 2020) 




CIRM has spent nearly all of its available funds.27 The bonds issued under 
Proposition 71 comprised nearly all of CIRM’s funding, with a relatively small amount of 
funding from investment income, private donations, or other sources.28 As of June 2020, 
CIRM had $30 million remaining for grants, and it has decreased its staff from a peak of 50 
full-time staff to 35 full-time staff, planning to maintain some staff while the remaining 
projects are completed.29 
 
On the federal level, NIH awards grants to fund research nationwide and has a 
budget of $40.3 billion for medical research in 2020.30 More than 80% of NIH’s funding is 
dispersed through competitive grants to research institutions across the nation and $2.1 




 Economists at the University of Southern California conducted an economic impact 
study of CIRM in October 2019.32 This study estimated that CIRM has added $15.4 billion 
into the U.S. economy over 14 years.33 The estimates are based on economic stimulus 
created by CIRM grants; co-funding; partnership funding; leverage funding of Alpha Stem 
Cell Clinics, follow-on funding, and CIRM operating expenditures.34 This study was funded by 
CIRM. 
 
a) Estimated Economic Impacts on California Economy 
 
 CIRM-funded activities added to the California economy $10.7 billion in scientific 
research and development services, real estate, construction, hospitals, food manufacturing, 
wholesale trade, professional and health care services, and rental and leasing services.35 
These activities increased state and local tax revenues by $434.1 million between 2005 and 
2018.36 Even if Proposition 14 does not pass, CIRM is still estimated to increase state and 
 
27 Stem Cell Research, LEGISLATIVE ANALYST’S OFFICE, as of 12/2/2019 available at 
https://lao.ca.gov/ballot/2019/190611.pdf. 
28 Id. 
29 LEGISLATIVE ANALYST’S OFFICE, supra note 1. 
30 Budget, NATIONAL INSTITUTES OF HEALTH, https://www.nih.gov/about-nih/what-we-do/budget (last visited Sept. 
22, 2020).  
31 Funding, NATIONAL INSTITUTES OF HEALTH, https://report.nih.gov/categorical_spending.aspx (last visited Oct. 7, 
2020). 
32  Dan Wei & Adam Rose, Economic Impacts of the California Institute of Regenerative Medicine (CIRM), 
Schaeffer Center for Health Policy and Economics, Sol Price School of Public Policy, USC (Oct. 3, 2019) 
avaiable at https://www.cirm.ca.gov/sites/default/files/CIRM_Economic%20Impact%20Report_10_3_19.pdf.  
33 Id. 
34 Id. 
35 Id.; Joyce E. Cutler, California Stem Agency Put $15 Billion into U.S. Economy (1), BLOOMBERG LAW, (Oct. 9, 
2019, 7:09PM), https://news.bloomberglaw.com/health-law-and-business/california-stem-cell-agency-put-15-
billion-into-u-s-economy (last visited Sept. 22, 2020). 
36 Wei, supra note 32. 
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local tax revenues by an additional $207.2 million through 2023.37 Additionally, CIRM 
created roughly 44,010 full-time equivalent jobs between 2005 and 2018, half of which offer 
salaries higher than the state average.38 By 2023, that number is expected to increase to 
56,549.39  
 
b) Estimated Economic Impacts on the Rest of U.S. 
 
The quantified impact on the rest of the U.S. economy through 2023 is an estimated 
increase of $4.7 billion in gross outcome.40 Additionally, federal taxes from CIRM-related 
activities are estimated to have increased by $726.6 million while adding an additional 
25,816 jobs nationwide.41  
 
D. Relevant Litigation 
 
After voters approved Proposition 71, the California Family Bioethics Council 
challenged its constitutionality.42 In this case, the opponents made four allegations.43 First, 
they alleged that the initiative violated California’s single-subject requirement for initiatives 
because some of the provisions of the proposition covered more than stem cell research.44 
Second, they alleged that the Proposition 71 ballot materials were misleading in a way that 
violated due process of law.45 Third, they alleged that the initiative created a taxpayer-
funded entity that was not under the direct control of the state as required.46 Fourth, they 
alleged that the Independent Citizens’ Oversight Committee (ICOC) had an inherent conflict 
of interest because it would both award grants and include representatives of institutions 
that might receive grants.47 The trial court rejected these allegations, as did the appellate 
court.48 
 
E. The Proposition 
 
1. Effects of Proposition 14 
 
 If approved, Proposition 14 will allow for the issuance of $5.5 billion in general 







42 California Family Bioethics Council v. California Institute for Regenerative Medicine, 147 Cal App 4th 1319 






48 Id. at 1330. 
49 Cal. Proposition 14 (2020) (adding CAL. HEALTH & SAFETY CODE § 125290.75). 
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research to develop treatments and cures for serious diseases and conditions.50 Proposition 
14 will also set aside $1.5 billion for research and therapy of brain and central nervous 
system diseases.51 
 
2. Differences Between Proposition 14 and Proposition 71 
 
Although much of the text is substantially the same, Proposition 14 not only renews 
this funding, but adds and updates the programs implemented by Proposition 71.52 There 
are four major updates.53 First, Proposition 14  makes changes to improve access to 
therapies for California patients with insufficient funds, establishing an additional working 
group to focus on this effort.54 Second, it increases the number of members on the ICOC 
from 29 to 35.55 Third, it caps the number of bond-funded, full-time CIRM employees at 70, 
with an additional 15 dedicated to improving access to stem-cell-derived therapies and 
treatments.56 Fourth, it establishes training programs for undergraduate students and 
fellowships for graduate students related to advanced degrees and technical careers in 
stem cell research, treatments, and cures.57 
 
Currently CIRM has three working groups that advise the ICOC, one each for 
medical research funding, research standards, and facilities grants.58 Proposition 14 will 
create a fourth working group that will focus on improving access to treatments and cures.59 
It will also increase ICOC public meetings from two to four per year and place restrictions 
on the royalty revenues received through intellectual property agreements that go to the 
General Fund.60 The royalties will be used to offset the costs to California patients who have 
insufficient means to purchase the treatment from institute-funded research instead of being 
used for other General Fund items.61  
 
Under Proposition 14, the additional members of the ICOC will include a faculty 
member, physician/scientist, researcher, or executive officer from the UCSF Fresno/Clovis 
campus to promote geographic diversity and access; an additional member may be 
appointed by the Governor from the California State University system who has an 
advanced degree in biological sciences; the Governor and Lieutenant Governor each shall 
appoint an additional member that will include someone from a mental health conditions 
 
50 Id. 
51 Id. adding CAL. HEALTH & SAFETY CODE § 125290.70.5(c). 
52 California Proposition 14, Stem Cell Research Bond Initiative (2020), BALLOTPEDIA, 
https://ballotpedia.org/California_Proposition_14,_Stem_Cell_Research_Institute_Bond_Initiative_(2020) (last 
accessed Sept. 23, 2020). 





58 Cal. Proposition 71 (2004) (amending CAL. HEATH & SAFETY CODE § 125290.50). 
59 Cal. Proposition 14 (2020) (adding CAL. HEALTH & SAFETY CODE § 125290.75). 
60 Id. 
61 Id. amending CAL. HEALTH & SAFETY CODE §125290.30(f)(1), (j)(1). 
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background; and the Treasurer and Controller shall each appoint a nurse with experience 
in clinical trial management and/or stem cell or genetic therapy delivery.62 Additionally, the 
initiative imposes a new employee cap of 70 that does not include members of the ICOC 
and 15 additional employees designated for the development of policies and programs to 
help make treatments available and affordable for Californians.63 
 
If approved, Proposition 14 will establish a scientific advisory task force to provide 
expert guidance to address specific objectives in areas under the institute’s jurisdiction, 
including scientific, policy, ethical, financial, and technical matters.64 The Chair and the 
President shall each appoint an equal number of members with expertise in the area for 
which advice is sought, including at least one member with a patient advocate 
perspective.65  
 
The initiative also amends Proposition 71 by adding additional accountability 
requirements that the ICOC shall update, at its discretion.66 These include the standards 
relating to conflict of interest rules, ethical research and treatment, and independent 
financial audits, to be generally aligned with standards adopted by the National Academy 
of Sciences.67 
 
F. Path to the Ballot 
 
 After helping to draft the proposition, Robert N. Klein filed the ballot initiative on 
October 10, 2019.68 Though the proponents did suspend signature gathering due to the 
coronavirus pandemic, on May 5, 2020, the proponents submitted 924,216 signatures for the 
ballot initiative.69 Only 623,212 valid signatures were required.70 
 
G. Where the Money Goes and How It is Decided 
 
 Proposition 14 includes several rules and guidelines how the $5.5 billion will be 
allocated.71 First, at least $1.5 billion of the $5.5 billion is reserved for grants for research 
and therapy for Alzheimer’s, Parkinson’s, stroke, epilepsy, and other brain and central 
nervous system diseases and conditions.72 Second, royalty revenues received through 
intellectual property agreements resulting from grants and loans awarded under 
 
62 Id. amending CAL. HEALTH & SAFETY CODE § 125290.20(a). 
63 Id. amending CAL. HEALTH & SAFETY CODE § 125290.45(b)(1). 
64 Id. adding CAL. HEALTH & SAFETY CODE § 125290.76 
65 Id. 
66 Id supra note 64. 
67 Id. adding CAL. HEALTH & SAFETY CODE § 125290.30(l). 
68 BALLETOPEDIA, supra note 52; Zoom Interview with Robert N. Klein, Proponent, Sacramento, Calif. (Sept. 25, 
2020) (on file with the California Initiative Review). 
69 Id. 
70 Id. 
71 Cal. Proposition 14 (2020) (adding CAL. HEALTH & SAFETY CODE § 125290.70.5). 
72 Id. adding CAL. HEALTH & SAFETY CODE § 125290.70.5(c). 
8 
Proposition 14 will be placed in an interest-bearing account in the General Fund.73 That 
amount and its interest will be used to offset the costs of providing treatments and cures 
from institute-funded research to California patients with insufficient means.74 
  
 The rest of the proceeds of the bonds sold for Proposition 14 will be divided by 
certain percentage parameters. First, no less than 95.5% of the proceeds will be used for 
grants and grant oversight.75 Of the 95.5%, no less than 98% of those proceeds will be used 
for research, therapy development, and therapy delivery grants.76 The other up to 2% of 
those proceeds will be used for research consulting in support of access to and 
affordability of treatments and cures.77  
 
The ICOC determines the amounts of the grants and to whom they are given.78 
Members of the ICOC are not allowed to participate in or influence decisions regarding 
approval of grants for their employers, though they may participate in decisions awarding 
grants for the purpose of research involving a disease from which a family member is 
suffering or in which they have interests as representatives of disease advocacy 
organizations.79 Since it began granting funds in 2006, CIRM has recorded and published 
each grant, listing the grant type, the grant title, the institution with which the researcher is 
associated, the researcher’s name, the award amount, the disease focus (beginning in 
2007), the type of stem cell used (beginning in 2007), the grant number, the award’s status, 
and the start and end dates.80 
 
 The remaining 4.5% of the proceeds have more flexibility. Up to 3% of the proceeds 
may be used for the implementation costs of research and research facilities, which include 
development, administration, and oversight of the grant-making process.81 Up to 3% of the 
proceeds will be used for costs of general administration of CIRM.82 Up to 1% of the 
proceeds may be used to pay for up to 15 full-time employees for CIRM.83  
 
 Additionally, Proposition 14 contains provisions that require grantees that gain 
revenue from their institute-funded projects to pay certain amounts back to the General 
Fund, dependent on factors such as the amount of revenue received, whether funding 
sources other than CIRM directly contributed to the development of the therapy or 
 
73 Id. amending CAL. HEALTH & SAFETY CODE § 125290.30(j)(1). 
74 Id.  
75 Id. adding CAL. HEALTH & SAFETY CODE § 125290.70.5(a)(1)(A). 
76 Id. adding CAL. HEALTH & SAFETY CODE § 125290.70.5(a)(1)(B). 
77 Id.  
78 Id. supra note 71 amending CAL. HEALTH & SAFETY CODE § 125290.40(c). 
79 Cal. Proposition 14 (2020) (amending CAL. HEALTH & SAFETY CODE §§ 125290.30(i)(1)(A–B)). 
80 Grants, CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE, https://www.cirm.ca.gov/grants (last accessed Sept. 
23, 2020). 
81 Id. supra note 79, adding CAL. HEALTH & SAFETY CODE § 125290.70.5(a)(1)(C). 
82 Id. adding CAL. HEALTH & SAFETY CODE § 125290.70.5(a)(2)(A). 
83 Id. adding CAL. HEALTH & SAFETY CODE § 125290.70.5(a)(2)(B). 
9 
technology, and whether the grantee self-commercializes a product resulting from an 
invention that arises from research funded by CIRM.84 
 
III. DRAFTING ISSUES 
 
A. Ambiguous Terms 
 
 Proposition 14 includes a clause requiring no more than 1% of proceeds be used to 
pay for up to 15 full-time employees “over 10-15 or more years.”85 The drafters state that this 
was left ambiguous to allow for these employees to be retained after other funding runs out 
to help wind down the ongoing grants, if necessary.86 Another vague provision is the 
additional accountability requirement, which is framed as a requirement, but only requires 
that the ICOC update its standards relating to conflict of interest rules, ethical research and 
treatment, and independent financial audits at its discretion to be generally aligned with 
standards adopted by the National Academy of Sciences.87 
 
Further, in the additions regarding CIRM’s plan to assist California patients in 
obtaining therapies if those patients have insufficient funds, Proposition 14 does not include 
a definition of a “California patient” or how “insufficient funds” will be determined. This 
could cause confusion regarding (1) whether patients must be California residents to 
receive assistance, and, if so, for how long they must be residents, and (2) whether one’s 
funds are sufficiently “insufficient” to qualify for assistance. The drafters of the proposition 
note that this was done intentionally to leave that determination to the state and the board 
of CIRM.88 
 
B. Severability Clause 
 
 If any provisions of the text are found invalid, Proposition 14 includes a severability 
clause allowing the valid provisions to remain.89 The majority of the text of Proposition 14 is 
similar to the text in Proposition 71, none of which has been held invalid. Though there are 
new added and amended provisions, they are not similar to the types of provisions that 
have been held invalid in other circumstances, as discussed below, and it is unlikely that 







84 Id. amending CAL. HEALTH & SAFETY CODE § 125290.30(j)(2). 
85 Id. adding CAL. HEALTH & SAFETY CODE § 125290.70.5(a)(2)(B). 
86 Zoom Interview with Robert N. Klein, supra note 68. 
87 Id. supra note 67. 
88 Zoom Interview with Robert N. Klein, supra note 68. 
89 Cal. Proposition 14 at § 27 (2020). 
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IV. CONSTITUTIONAL AND STATUTORY ISSUES 
 
A. Federal Constitution 
 
 The Commerce Clause of the Constitution grants Congress the power to regulate 
interstate commerce.90 Because of this power, states cannot pass legislation that 
discriminates against or excessively burdens interstate commerce.91 The federal government 
has a particular interest in preventing states from enacting policies that favor citizens or 
businesses of that state at the expense of non-citizens conducting business within that 
state.92 However, when the state is acting as a business, these preferential policies are 
allowed.93 This is called the market participation exception.94  
 
Here, CIRM has been established to be an institution under the “exclusive 
management and control of the State,” so its structure and actions affecting the market 
could be attributable to California.95 Proposition 14 includes a provision which requires the 
ICOC to “establish standards to ensure that grantees purchase goods and services from 
California suppliers to the extent reasonably possible, in a good faith effort to achieve a 
goal of more than 50 percent of such purchases from California suppliers,” a provision 
which, on its face, seems to favor businesses within the state.96 However, by purchasing 
goods and services, CIRM acts business in the marketplace, and thus it is likely the market 
participation exception applies and Proposition 14 does not violate the Constitution. 
 
B. State Constitution 
 
1. General Obligation Bonds 
 
 State general obligation bonds allow the state of California to borrow money from 
investors to fund public works projects.97 The state commits to repay the bonds using the 
state General Fund and requires a majority of voters to approve general obligation 
bonds.98 After selling the bonds the state makes regular payments over time until the bonds 
are paid off.99  
 
 
90 U.S. CONST. art. 1, § 8, cl. 3. 
91 Commerce Clause, LEGAL INFORMATION INSTITUTE, Cornell Law School, 




95 California Family Bioethics Council, supra note 42 at 1353. 
96 Cal. Proposition 14 (2020) (adding CAL. HEALTH & SAFETY CODE § 125290.30(k)). 
97 Bonds 101 (2016), CALIFORNIA STATE TREASURER, available at 
https://www.treasurer.ca.gov/publications/bonds101.pdf. 
98 CAL. CONST., art. 16 §§ 1, 1.5. 
99 CAL. SEC’Y OF STATE, OFFICIAL VOTER INFORMATION GUIDE: CALIFORNIA GENERAL ELECTION, TUESDAY,  November 3, 2020, 
at 78–79, available at https://voterguide.sos.ca.gov/voter-info/overview-state-bond-debt.htm.  
11 
As of 2020, the state has about $80 billion in General-Fund-supported bonds that it is 
making annual principal and interest payments on, and it is estimated that the state is 
paying $7 billion annually from the General Fund to repay these bonds.100 The voters and 
legislature have approved around $38 billion bonds that have yet to be sold.101 If voters 
approve Proposition 14, it is projected to increase the portion of the state’s annual General 
Fund revenues that are set aside to pay for bond debt, the debt-service ratio, by about one-
fifth of one percentage point compared to what it would otherwise have been over the next 
couple of years.102 
 
2. Single-Subject Rule 
 
 The California Constitution requires voter initiatives to have a single subject.103 The 
provisions of the initiative must be reasonably germane to each other.104 The phrase 
“reasonably germane” requires that the provisions have a reasonable and common-sense 
relationship among their various components in furtherance of a common purpose.105 
  
 There were two lawsuits challenging the constitutionality of Proposition 71. As a 
result, California’s First District Court of Appeal held, in part, that Proposition 71 did not 
violate the single-subject rule.106 In that case, the court determined the trial court was 
correct in finding that the overarching subject of Proposition 71 was stem cell research and 
funding and that the other portions such as the development of the ICOC, inclusion of 
“other vital research opportunities” catch-all, and other administrative sections were 
reasonably interrelated and do not violate the single-subject rule.107 Because Proposition 14 
is an update and renewal of Proposition 71, most of the text is the same, and therefore that 
text almost certainly meets the single-subject rule. Proposition 14 does add new 
considerations regarding efforts to prioritize some funding for  
California patients who would otherwise have insufficient funds, but based on previous case 
law, it seems likely those additions would be ‘reasonably germane’ to the overarching 
subject of stem cell research and funding. 
 
V. PUBLIC POLICY ISSUES 
 
A. Proponents’ Arguments 
 
On the whole, the proponents essentially assert that the research performed due to 





103 CAL. CONST., art. 2 § 8(d). 
104 Legislature v. Eu, 54 Cal.3d 492, 512 (1991). 
105 Id. at 513. 
106 California Family Bioethics Council, supra note 42 at 1337. 
107 Id. at 1342-43. 
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would help sustain those projects and begin new ones.108 The Yes on 14 campaign states 
that Proposition 71 has led to more than 90 clinical trials, two FDA-approved drugs for the 
treatment of two forms of fatal blood cancers, and over 2,900 published medical 
discoveries.109 Further, proponents assert that CIRM-assisted research has led to some other 
promising cancer therapies that have reversed, over the course of two years, 80% mortality 
rates to 85% survival rates starting in stage four patients.110 There are over 800 patents 
pending for CIRM-funded discoveries, which proponents add would be a future source of 
state revenue.111 They have added that this proposition is necessary to continue supporting 
ongoing trials and refining and testing discoveries.112 Additionally, proponents add that, 
while many of the treatments are still in the early stages of clinical trials, there have been 
the following improvements to individuals lives: cancer patients who had exhausted all 
other therapies are now in remission; paralysis patients have regained upper body function; 
blind patients are regaining their eyesight; a cure has been developed for the once-fatal 
“bubble baby” disease; patients with Type 1 Diabetes have begun producing their own 
insulin; and multiple clinical trials are underway for leukemia, non-Hodgkin lymphoma, 
ovarian cancer, and more.113 
 
 Other supporters of this proposition include the University of California Board of 
Regents; members of the Yes on 14 coalition: Californians for Stem Cell Research, 
Treatments & Cures, which includes over 83 patient advocate organizations, several other 
organizations and individuals, including several Nobel Prize winners.114 One notable group 
that supports Proposition 14 is Seth and Lauren Rogen’s Hilarity for Charity non-profit, which 
the two created because Lauren Rogen’s mother suffered from Alzheimer’s; Seth Rogen 
even voiced a character called Stemmy the Stem Cell in a promotional video for Yes on 
14.115 
 
Another factor proponents, within and without CIRM and its grantees, note is the 
draw the potential for future scientific advancements, stating that the state’s funding attracts 
the best minds to contribute to the field of science and perhaps to establish their own 
businesses here; this benefits California’s economy and citizens, as well as the citizens of 
 
108 BALLETOPEDIA, supra note 52. 
109 By the Numbers, YES ON 14: CALIFORNIANS FOR STEM CELL RESEARCH, TREATMENTS AND CURES COMMITTEE, 
https://caforcures.com/by-the-numbers/ (last accessed Sept. 21, 2020). 
110 Zoom Interview with Robert N. Klein, supra note 68. 
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this nation and others.116 According to some, Proposition 71 has made the state the “center 
of the stem cell universe.”117 Proponents are concerned that potential consequences of this 
funding not being renewed include the state’s loss of revenue and prestige regarding jobs, 
intellectual property, and leadership in the science sector.118 If Proposition 14 is not 
approved, CIRM will take further planned steps to wind down the program, including 
reducing its staff.119 
 
B. Opponents’ Arguments 
 
 Opponents of the proposition argue that CIRM has issues regarding conflicts of 
interest and a lack of legislative oversight.120 These claims appear to be similar to the 
claims that were dismissed by the courts in the California Family Bioethics Council case 
regarding Proposition 71.121 However, opponents assert that Proposition 14 further adds to 
those concerns by “outsourc[ing] critically important decisions about ethical standards to an 
unaccountable national committee.”122 Presumably, opponents make this argument because 
the proposition adds a provision regarding additional accountability requirements that 
require the ICOC to update its standards relating to conflict of interest rules, ethical 
research and treatment, and independent financial audits at its discretion “to be generally 
aligned with standards adopted by the National Academy of Sciences to the extent that 
such standards are consistent with constitutional and statutory requirements applicable to 
the institute.”123 Opponents further argue that the ICOC is too large at 29 members, so they 
dislike the addition of 6 more members.124 Regarding conflicts of interest in particular, 
opponents acknowledge that members of the ICOC cannot participate in votes to grant 
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 Opponents also note that the original rationale for this funding, the fact that the 
federal government had restricted funding for stem cell research at the time Proposition 71 
was passed, has been eliminated because most of the federal funding restrictions have 
been lifted.126 They also state that the two cancer treatments CIRM helped fund did not use 
embryonic stem cells, so they could have been federally funded even under the previous 
restrictions.127 They also argue that voting on this sort of investment should be stalled until 
after the election, asserting that, if Democrats get more power, there should be growing 
support for embryonic stem-cell research at the federal level, which is from where they 
argue such funding should originate.128  
 
Opponents also assert that private industry has stepped up, though this seems to be 
difficult to substantiate.129 Proponents respond to that argument by noting that private 
industry, due to its focus on financial return, is unlikely to fund high-risk projects, while 
government agencies can fund research with a focus on benefits to the public rather than 
on making money.130  
 
 The named opponent on the California Voter Information Guide, John Seiler, asserts 
that the state cannot afford Proposition 14 “during this economic and budget crisis” and 
CIRM has “management challenges and poor results.”131 He also argues that “[s]ervicing 
debt of Prop. 14 could increase pressure for higher taxes or layoffs of nurses, first 
responders and other public employees.”132 When contacted for further information, he did 
not provide sources that proved these claims. 
 
 Right to Life of Central California, one opponent of Proposition 14, is a pro-life non-
profit that is focused on activities such as having its employees and volunteers speak with 
individuals entering and leaving Planned Parenthood and “defend[ing] the sanctity of all 
human life.”133 Right to Life of Central California states that it is against embryonic stem cell 
research as a whole because they believe it cheapens human life and is irresponsible 
spending.134 They argue that the human embryos used in some of the research funded by 
CIRM are unique human organisms, and their use for research instrumentalizes human 
life.135 They also argue that it is a waste of money because the public has not yet seen the 
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benefits of this research, though this can be contradicted by the proponents’ list of 
accomplishments above.136 They state they would not  
support CIRM unless it exclusively turned to adult stem cells and induced pluripotent stem 
cells, which are derived from skin or blood cells and reprogrammed back into an 
embryonic-like state.137 
 




 There is a political action committee titled “Yes on 14: Californians for Stem Cell 
Research, Treatments and Cures.”138 As of September 22, 2020, it has received 
$6,605,389.51 in contributions and has spent $6,919,032.06.139 The largest donor is Robert N. 
Klein II (Klein Financial Corporation), contributing a total of $4,628,924.51, in-kind 
contributions making up $4,503,924.51 of that amount.140 Other top donors include Juvenile 
Diabetes Research Foundation, Open Philanthropy Action Fund, Ann S. Tsukamoto, and One 
Mind for Research, Inc. Juvenile Diabetes Research Foundation describes itself as the 
leading global organization funding type 1 diabetes research.141 Open Philanthropy Action 
Fund is a 501(c)(4) social welfare organization.142 Ann S. Tsukamoto is a doctor who has 
spent over 20 years working in stem cell biology, and her work has led to many 
advancements, including in comprehending the blood systems of cancer patients.143 One 
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 Though there is a political action committee for No on Proposition 14 registered with 
the California Secretary of State, it has not yet recorded any filings.145 We have not found 
any readily available evidence about campaign contributions the named opponent, John 
Sieler, has made.146 
 
D. Fiscal Considerations 
 
 Proposition 14 has an estimated total cost, including interest, of approximately $7.8 
billion, equaling an average of about $260 million per year over 30 years; this is about 4% 
more than the state currently spends from the General Fund on its bond debt.147  
 
An economic impact study, funded by CIRM, focused on the various economic 
impacts of CIRM over and above its main functions of improving health and well-being.148 
The increases in economic output, employment and tax revenues represent valuable co-
benefits of CIRM activities.149 Such benefits emanate not only from CIRM direct funding 
commitments but also from co-funding, partnership funding, follow-on funding, and 
additional leveraged funding.150 Not only the direct impacts but also various indirect 
impacts were quantified as CIRM and related expenditures ripple throughout the 
economy.151  
 
The report estimated that the total impacts of CIRM to date on the California 
economy have been: $10.7 billion of additional gross output (sales revenue); $641.3 million 
of additional state and local tax revenues; $726.6 million of additional federal tax revenues; 
and 56,549 additional full-time equivalent jobs, half of which offer salaries considerably 
higher than the state average.152 Additionally, the report determined that the impact on the 
economy of the rest of the U.S. has been: $4.7 billion of additional gross output; $198.7 
million of additional state and local tax revenues; $208.6 million of additional federal tax 
revenues; and 25,816 additional jobs.153 
 Another consideration is that, under Proposition 14, the bonds are to be sold over a 
period of no less than 10 years, with the cost of the bonds spread over 40 years so that the 
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repayment is aligned with the period of time over which California patients are expected to 




 Proposition 14 updates and renews the stem cell research program approved by 
Californian voters in 2004 (Proposition 71). Proposition 14 grants $5.5 billion in bonds for 
projects related to stem cell and other medical research aimed at developing treatments 
and cures for serious diseases such as diabetes, cancer, and heart disease, among many 
others.155 Over the years, many researchers have relied on this funding to perform studies 
and begin over 90 clinical trials, and it has led to two FDA-approved drugs to treat fatal 
blood cancer and over 2,900 published medical discoveries.156 Among other adjustments to 
the previous program such as increasing the number of members on the ICOC, Proposition 
14 adds an emphasis on supporting California patients with insufficient funds. 
 
 The proponents argue that this funding will continue to support innovation, develop 
therapies and cures for patients with serious diseases, and help maintain the jobs and 
prestige state-assisted stem cell research has brought to California. The opponents argue 
that Proposition 14 does not address their concern with CIRM’s lack of legislative oversight 
and potential conflicts of interest, though the California courts dismissed these concerns 
regarding Proposition 71 and Proposition 14 does contain safeguards for managing 
conflicts of interest. The opponents also argue that there is no longer as much of a need for 
this funding because the federal government has removed many of its previous restrictions 
on funding stem cell research. 
 
 A “yes” vote for Proposition 14 will allow the state to provide $5.5 billion in bonds for 
stem cell and other medical research, renewing and updating the program that has been 
in place since 2004.  
 
A “no” vote for Proposition 14 will not allow the state to provide $5.5 billion in bonds 
for stem cell and other medical research, and the current program will end after spending 
its remaining funding on projects to which it has already allocated money and completing 
its employment of CIRM staff members. 
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